Stockscreener 앱 받기
6.10
5.35%
0.31
시간 외 거래:
6.11
0.01
+0.16%
Abeona Therapeutics Inc 주식(ABEO)의 최신 뉴스
Abeona Therapeutics (ABEO): Stifel Lowers Price Target | ABEO St - GuruFocus
Abeona Therapeutics (ABEO): Stifel Lowers Price Target | ABEO Stock News - GuruFocus
Stifel cuts Abeona Therapeutics price target to $20, maintains Buy By Investing.com - Investing.com India
Abeona Therapeutics (ABEO) Receives Revised Price Target Amid Positive Developments | ABEO Stock News - GuruFocus
Abeona Therapeutics: Q1 Earnings Snapshot - CT Insider
Abeona Therapeutics (ABEO) Transitions to Commercial Stage with ZEVASKYN Launch - GuruFocus
Abeona Therapeutics (ABEO) Target Price Raised Following FDA Approval and Strategic Sale | ABEO Stock News - GuruFocus
Earnings call transcript: Abeona Therapeutics beats EPS forecast in Q1 2025 - Investing.com
Abeona Therapeutics (ABEO) Exceeds EPS Estimates, Bolstered by S - GuruFocus
ABEO Shows Decrease in Cash Reserves Before PRV Sale Completion - GuruFocus
Abeona Therapeutics (ABEO) Launches ZEVASKYN, A Milestone in Gen - GuruFocus
Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates | ABEO Stock News - GuruFocus
ABEO Shows Decrease in Cash Reserves Before PRV Sale Completion | ABEO Stock News - GuruFocus
Abeona Therapeutics (ABEO) Launches ZEVASKYN, A Milestone in Gene Therapy | ABEO Stock News - GuruFocus
ABEONA THERAPEUTICS INC. SEC 10-Q Report - TradingView
Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates - GlobeNewswire
Breakthrough: First-Ever Gene Therapy for Rare Skin Disease Launches as Abeona Secures $155M Deal - Stock Titan
US FDA Orphan Drug Rare Disease Market Clinical Trials Drug Sales Insight 2030 - GlobeNewswire Inc.
UPDATE -- Abeona Therapeutics® and Lurie Children's Open First C - GuruFocus
Abeona Therapeutics® and Lurie Children's Open First Center for - GuruFocus
Abeona Therapeutics (ABEO) Initiates Gene Therapy Rollout for Sk - GuruFocus
Best Momentum Stocks to Buy for May 8th - The Globe and Mail
UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene ... - Eagle-Tribune
UPDATE -- Abeona Therapeutics® and Lurie Children's Open - GlobeNewswire
Breakthrough Gene Therapy ZEVASKYN Launches: First Treatment Center Opens for Rare Skin Disease RDEB - Stock Titan
Abeona Therapeutics® and Lurie Children's Open First Center - GlobeNewswire
Abeona Therapeutics And Lurie Children's Open First Center For Zevaskyntm Gene Therapy - marketscreener.com
First-Ever Gene Therapy Treatment Center Opens for Devastating Skin Disease RDEBWhat Patients Need to Know - Stock Titan
Abeona Therapeutics: Strong Buy Rating Backed by Financial Stability and Strategic Growth Initiatives - TipRanks
Abeona Therapeutics (ABEO) Expected to Announce Earnings on Wednesday - Defense World
Abeona secures cash runway with $155m priority review voucher sale - Yahoo
Traders Buy Large Volume of Abeona Therapeutics Call Options (NASDAQ:ABEO) - Defense World
Abeona sells FDA voucher for $155 million, eyes profitability By Investing.com - Investing.com Canada
Cleveland company enters $155M agreement to sell FDA voucher - Crain's Cleveland Business
Abeona Therapeutics to Sell Zevaskyn Priority Review Voucher for $155 Million; Shares Rise - marketscreener.com
Abeona sells speedy drug review voucher for $155M - BioPharma Dive
Abeona sells FDA voucher for $155 million, eyes profitability - Investing.com Australia
Abeona Therapeutics (ABEO) Plans to Sell Priority Review Voucher for $155 Million | ABEO Stock News - GuruFocus
Abeona Therapeutics Sells Priority Review Voucher for $155M - TipRanks
Abeona Therapeutics® Enters into Agreement to Sell Priority Revi - GuruFocus
Abeona Therapeutics Enters Into Agreement To Sell Priority Review Voucher - marketscreener.com
Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million - GlobeNewswire
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ABEO Stock News - GuruFocus
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
StockWatch: Second Time’s the Charm for Abeona’s Gene Therapy - Genetic Engineering and Biotechnology News
Abeona Therapeutics’ Gene Therapy Gets FDA Nod For Treating Rare Genetic Skin Disease - MSN
HC Wainwright Brokers Reduce Earnings Estimates for ABEO - Defense World
HC Wainwright Forecasts Strong Price Appreciation for Abeona Therapeutics (NASDAQ:ABEO) Stock - Defense World
Abeona Therapeutics (ABEO) Gains FDA Approval for Gene Therapy | ABEO Stock News - GuruFocus
Institutional investors control 44% of Abeona Therapeutics Inc. (NASDAQ:ABEO) and were rewarded last week after stock increased 22% - simplywall.st
FDA approves Abeona’s $3.1m cell therapy for rare skin disease - MSN
ABEO: Zevaskyn Approved by FDA Raising Valuation to 11 - Smartkarma
Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease - Benzinga
Abeona Therapeutics (ABEO) Sees Price Target Boost Amid FDA Appr - GuruFocus
Abeona Stock Surges to 52-Week High: What's Behind The Move? - Benzinga
Abeona’s ZEVASKYN Gets FDA Nod for Rare Skin Disease - Contract Pharma
FDA approves Abeona’s Zevaskyn - The Pharma Letter
1.54%
7.58%
자본화:
|
볼륨(24시간):